Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
  • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/415—1,2-Diazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/08—Peptides having 5 to 11 amino acids
  • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/08—Drugs for disorders of the urinary system of the prostate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
  • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/02—Nutrients, e.g. vitamins, minerals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/04—Antineoplastic agents specific for metastasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
  • A61P5/28—Antiandrogens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
  • A61P5/30—Oestrogens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
  • A61P5/34—Gestagens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
  • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Definitions

• the instant invention is directed to methods for the
• Endothelin (ET) , a 21 amino acid peptide, is produced by
• tissues and cell types such as ovary, prostate,
• ET/ET receptor binding has been shown to constrict
• aldosterone, and catecholamines inhibit release of renin in
• a nonpeptide ET antagonist prevents post-ischaemic renal
• ET receptor antagonists can provide an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonist to an antagonists
• a method for preventing new bone metastases in a patient which comprises administering to the patient in need thereof a therapeutically effective amount of an endothelin ET-A receptor antagonist.
• an endothelin ET-A receptor antagonist an endothelin ET-A receptor antagonist .
• endothelin ET-A receptor antagonist optionally in the
• FIG. 1 illustrates levels of interleukin-6 (IL-6) in a
• FIG. 1 illustrates levels of prostate specific antigen
• Figure 3 illustrates VAS score levels relating to pain
• FIG. 4 illustrates crosslinked N-telopeptides
• Figure 5 illustrates bone alkaline phosphatase
• Figure 6 illustrates skeletal involvement in a subject
• Figure 7 illustrates acid phosphatase levels in a subject
• Endothelin receptor antagonists are employed in the following
• Endothelins are a family
• endothelin refers to a family of homologous proteins
• endothelin ET-A receptor antagonist includes
• ET-A receptor in a non-selective manner.
• the ET-A receptor and also antagonizes the ET-B receptor.
• primary cancer means cancer in a specific
• tissue which is first in time or in order of development.
• Primary cancers include, but are not limited to, breast,
• ovary myeloma, lymphoma, sarcoma, and osteosarcoma.
• cancer-related pain includes pain which arises
• R is - (CH 2 ) m -W;
• Z is selected from -C(R ⁇ s) (R19) - and -C(O)-;
• Rl and R2 are independently selected from hydrogen
• alkoxycarbonylalkyl hydroxyalkyl, haloalkyl, haloalkoxyalkyl
• alkoxyalkoxyalkyl thioalkoxyalkoxyalkyl , cycloalkyl
• dialkylaminocarbonylalkyl aminocarbonylalkenyl
• alkylsulfonylamidoalkyl heterocyclic, (heterocyclic) alkyl,
• R3 is selected from R_ ⁇ -C(0)-R5-, R4-Rs a -, R4 ⁇ C(0)-R5-
• R4 and R ⁇ are independently selected from (Rn) (Ri2)N-,
• aryl arylalkyl, heterocyclic, (heterocyclic) alkyl
• alkoxyalkyl hydroxyalkyl, haloalkyl, haloalkenyl
• haloalkoxyalkyl haloalkoxy, alkoxyhaloalkyl, alkylaminoalkyl
• R5 is selected from a covalent bond, alkylene, alkenylene, -N(R2 ⁇ ) -R 8-/ -R 8a ⁇ N ⁇ R 20 ⁇ _R 8 ⁇ ' _0-R 9 ⁇ / an d
• R6 is selected from loweralkyl, haloalkyl, alkoxyalkyl,
• R7 is a covalent bond, alkylene, alkenylene - (R21) - R 10- /
• R8 is selected from alkylene and alkenylene
• R9 is alkylene
• RlO is selected from alkylene and alkenylene
• R11 and R12 are independently selected from hydrogen
• alkynyl cycloalkyl, cycloalkylalkyl, aryl, heterocyclic
• arylalkyl (heterocyclic) alkyl, hydroxyalkyl, alkoxy,
• aminoalkyl trialkylaminoalkyl, alkylaminoalkyl,
• dialkylaminoalkyl and carboxyalkyl ;
• Rl3 is selected from amino, alkylamino and dialkylamino
• Rl4 is selected from aryl and R]_5-C(0)-;
• Rl5 is selected from amino, alkylamino and dialkylamino
• Rl6 is selected from loweralkyl, haloalkyl, aryl and
• Rl7 is loweralkyl
• Rl8 and R 9 are independently selected from hydrogen and
• R20 is selected from hydrogen, loweralkyl, alkenyl,
• R21 is selected from hydrogen, loweralkyl, alkenyl,
• haloalkyl alkoxyalkyl, haloalkoxyalkyl, aryl and arylalkyl;
• R22 s selected from a carboxy protecting group
• R23 is selected from covalent bond, alkylene, alkenylene
• R 2 4 is selected from hydrogen and loweralkyl
• R25 is alkylene
• R 2 6 i selected from loweralkyl, haloalkyl, alkenyl,
• alkynyl cycloalkyl, cycloalkylalkyl, aryl, arylalkyl,
• heterocyclic (heterocyclic) alkyl, alkoxyalkyl and alkoxy-
• R27 i selected from alkylene and alkenylene
• R5a is selected from alkylene and alkenylene
• R7 a is alkylene
• R 8a is selected from alkylene and alkenylene;
• Rg a is alkylene;
• R- j _ Qa is selected from alkylene and alkenylene
• R aa is selected from aryl and arylalkyl
• kk is selected from hydrogen and alkanoyl
• R cc is alkylene
• n 0-6;
• n 0 or 1
• z is 0-5;
• E is selected from hydrogen, loweralkyl and arylalkyl
• G is selected from hydrogen and a carboxy protecting
• ET A -selective endothelin antagonists specifically ET A -selective endothelin antagonists.
• Rg , Ry, R2g and R27 are as defined above.
• R5 is alkylene or R3 is R6-S(0)2 ⁇ R7- or R26-S (O) -R27- wherein
• R7 is alkylene
• R27 is alkylene
• R ⁇ and R26 are defined as
• R3 is R4-C (O) -N (R20) " 8" or
• R 6/ R 20 and R21 are defined as above.
• G is hydrogen or a carboxy protecting group
• R is tetrazolyl or R is
• R 16 is loweralkyl, haloalkyl or aryl, Z is -CH2-; Ri and R2 are independently selected from (i)
• aryl is phenyl substituted with one, two or three substituents
• alkanoyl-N-alkyl aminoalkyl and (x) alkylsulfonylamidoalkyl
• R3 is R4-C(0)-Rs- wherein R4 is (Rn) (Ri2)N- wherein R 1:] _
• R 12 are independently selected from loweralkyl, haloalkyl,
• alkoxyalkyl haloalkoxyalkyl, aryl, arylalkyl, heterocyclic
• R5 is alkylene; or R3 is R4-C (0) -N (R20) - R 8 ⁇ or Rg-S(0)2-
• R4 is loweralkyl, aryl, alkoxy
• alkylamino, aryloxy or arylalkoxy and R ⁇ is loweralkyl
• R7 is alkylene
• R26 is loweralkyl
• R27 is
• a yet more preferred embodiment of the invention is a compound of formula I or II wherein n is 0, R is -C(0) 2 -G
• G is hydrogen or a carboxy protecting group
• Z is -CH 2 - / Ri is (i) loweralkyl, (ii)
• alkenyl (iii) alkoxyalkyl, (iv) cycloalkyl, (v) phenyl, (vi)
• heterocyclic (alkyl) (x) arylalkyl, (xi) aryloxyalkyl , (xii)
• R 2 is substituted or unsubstituted
• R3 is R4-
• R21 are loweralkyl
• R4 is loweralkyl
• aryl is loweralkyl
• alkoxy
• alkylamino, aryloxy or arylalkoxy and Rg is loweralkyl
• haloalkyl alkoxyalkyl, aryl or arylalkyl.
• G is hydrogen or a carboxy protecting group
• haloalkyl or aryl Z is -CH2-, Ri is (i) loweralkyl, (ii)
• alkenyl (iii) alkoxyalkyl, (iv) cycloalkyl, (v) phenyl, (vi)
• heterocyclic (alkyl) (x) arylalkyl, (xi) aryloxyalkyl , (xii)
• R 2 is substituted or unsubstituted 1, 3-benzodioxolyl, 7-methoxy-1, 3-benzodioxolyl, 1,4-
• R3 is R4-
• R ] _ ⁇ and R 12 are independently selected from loweralkyl
• haloalkyl alkoxyalkyl, haloalkoxyalkyl, aryl, arylalkyl,
• G is hydrogen or a carboxy protecting group
• haloalkyl or aryl Z is -CH 2 -
• Ri is (i) loweralkyl, (ii)
• arylalkyl (vi) aryl, (vii) (N-alkanoyl-N-alkyl) aminoalkyl, or
• R3 is R4-C(0)-Rs- wherein R5 is alkylene and R4 is
• arylalkyl hydroxyalkyl, alkoxy, aminoalkyl
• G is hydrogen or a carboxy protecting group
• haloalkyl or aryl Z is -CH2-, Ri is (i) loweralkyl, (ii)
• alkylsulfonylamidoalkyl (vii) phenyl, or (ix) substituted or
• R 2 is substituted or unsubstituted 1, 3-benzodioxolyl, 7-
• substituent is selected from loweralkyl, alkoxy and halogen
• R3 is Rg-S (O) 2 ⁇ N(R2i) - R 10 _ wherein Rio is alkylene, Rg is
• arylalkyl and R 2 ⁇ is loweralkyl, haloalkyl, alkoxyalkyl,
• haloalkoxyalkyl aryl or arylalkyl .
• G is hydrogen or a carboxy protecting group
• haloalkyl or aryl Z is -CH2-, Ri is (i) substituted or
• alkoxyalkoxy (ii) loweralkyl, (iii) alkenyl, (iv)
• R3 is
• Rg is loweralkyl, haloalkyl, alkoxyalkyl or
• haloalkoxyalkyl and R 2 ⁇ is loweralkyl, haloalkyl, alkoxyalkyl
• G is hydrogen or a carboxy protecting group
• Z is -CH 2 -
• R is loweralkyl, alkenyl, heterocyclic
• R3 is R4-
• _l and R 12 are independently selected from alkyl, aryl,
• G is hydrogen or a carboxy protecting group, tetrazolyl or -C (0) -NHS (O) 2 R- ] _ wherein R 16 is loweralkyl or
• haloalkyl Z is -CH 2 -
• Ri is substituted or unsubstituted 4-
• substituent is selected from alkoxy, alkoxyalkoxy
• R 2 is 1,3-
• R3 is R4-C(0)-Rs- wherein R5 is alkylene
• R4 is ( R n) (R ⁇ 2 )N- wherein and R- j _ 2 are independently
• alkoxy, aminoalkyl, trialkylaminoalkyl, or heterocyclic alkoxy, aminoalkyl, trialkylaminoalkyl, or heterocyclic.
• G is hydrogen or a carboxy protecting group
• R- j _g is loweralkyl or haloalkyl
• Z is -CH -
• Ri is loweralkyl, alkenyl, heterocyclic
• alkyl aminoalkyl, alkylsulfonylamidoalkyl, phenyl, or
• R 2 is 1, 3-benzodioxolyl, 1, -benzodioxanyl,
• R3 is R4-
• R ll an ⁇ ⁇ R 12 are independently selected from loweralkyl, aryl,
• arylalkyl hydroxyalkyl, alkoxy, aminoalkyl
• G is hydrogen or a carboxy protecting group
• Z is -
• R i is substituted or unsubstituted 4-methoxyphenyl, 4-
• substituent is selected from alkoxy, alkoxyalkoxy
• R 2 is 1, 3-benzodioxolyl, 1, 4 -benzodioxanyl,
• R3 is R4-
• R ll an ⁇ ⁇ R 12 are independently selected from loweralkyl .
• G is hydrogen or a carboxy protecting group
• Z is -
• Ri is substituted or unsubstituted 4 -methoxyphenyl
• substituent is selected from alkoxy, alkoxyalkoxy
• R 2 is 1, 3-benzodioxolyl, 1, 4 -benzodioxanyl,
• R3 is R4-
• _ . is loweralkyl and R 12 is aryl .
• G is hydrogen or a carboxy protecting group,- Z is -
• Rl is substituted or unsubstituted 4-methoxyphenyl, 3- fluoro-4-methoxyphenyl, 3 -fluorophenyl, 2 -fluorophenyl, 3-
• substituent is selected from loweralkyl
• R 2 is haloalkyl, alkoxy, alkoxyalkoxy and carboxyalkoxy
• R3 is Rg-
• G is hydrogen or a carboxy protecting group
• Z is -
• R i is substituted or unsubstituted 4 -methoxyphenyl, 3-
• R 2 is
• R3 is R4-
• R l;L is alkyl and R 12 is selected from aryl, aminoalkyl,
• G is hydrogen or a carboxy protecting group
• Z is -
• R i is loweralkyl, alkenyl, heterocyclic (alkyl),
• aryloxyalkyl aryalkyl, aryl, (N-alkanoyl-N-alkyl) aminoalkyl
• R3 is R4-C(0)-Rs- wherein R5
• R4 is (Rn) (R ⁇ 2 )N- wherein R- ⁇ and R 12 are
• alkyl independently selected from alkyl, aryl, hydroxyalkyl, alkoxy,
• R4 is (Rn) (R ⁇ 2 )N- as defined
• R5 is alkylene
• Ri is loweralkyl
• R3 is R4-C(0)-Rs- wherein R4 is
• Rl is alkenyl
• R3 is R4-C(0)-Rs- wherein R4 is
• R11 (R11) (Ri 2 )N- as defined therein and R5 is alkylene.
• R is heterocyclic (alkyl)
• R3 is
• R5 is alkylene
• Rl is aryloxyalkyl
• R3 is R4-C(0)-Rs- wherein R4 is
• R 4 is a compound of formula I or II wherein n is 0, Z is -CH -, R l is arylalkyl, and R 3 is R 4 -C(0)-Rs- wherein R 4 is
• R ll (R ⁇ 2 )N- as defined therein and R 5 is alkylene.
• Ri is aryl
• R 3 is R 4 -C(0)-Rs- wherein R 4 is (Rn) (R ⁇ 2 )N-
• R 5 is alkylene
• Another most highly preferred embodiment of the invention is a compound of formula I or II wherein n is 0, Z is -CH -,
• R l is (N-alkanoyl-N-alkyl) aminoalkyl
• R 3 is R 4 -C(0)-Rs-
• R 4 is (Rn) (R ⁇ 2 )N- as defined therein and R 5 is
• R l is alkylsulfonylamidoalkyl
• R 3 is R 4 -C(0)-Rs- wherein
• R 4 is (Rn) (Ri 2 )N- as defined therein and R 5 is alkylene.
• a particularly preferred compound of formula I is a
• endothelin ET-A receptor antagonist may be used, such as those disclosed in U.S. Patent Nos.
• inhibitor is defined to include its generally
• the present method includes both medical
• the methods of the present invention are useful in men as
• present invention are useful in men, more preferably men with
• treat cancers can be demonstrated according to the method
• primary cancer such as breast, prostate, lung,
• kidney thyroid, myeloma, lymphoma, sarcoma, osteosarcoma, and
• the compounds of the present invention can be used in the form of salts derived from inorganic or organic acids.
• salts include but are not limited to the following: acetate,
• camphorsulfonate, digluconate, cyclopentanepropionate camphorsulfonate, digluconate, cyclopentanepropionate
• pectinate persulfate, 3-phenylpropionate, picrate, pivalate,
• containing groups can be quaternized with such agents as
• loweralkyl halides such as methyl, ethyl, propyl, and butyl
• halides such as decyl, lauryl, myristyl and stearyl chlorides
• acids which may be employed to form pharmaceutically acceptable acid addition salts include such acids
• inorganic acids as hydrochloric acid, sulphuric acid and
• a suitable base such as the hydroxide, carbonate or
• Such pharmaceutically acceptable salts include, but
• earth metals such as sodium, lithium, potassium, calcium,
• ammonium quaternary ammonium, and amine cations, including,
• ammonium but not limited to ammonium, tetramethylammonium,
• base addition salts include diethylamine, ethylenediamine,
• the compounds of formulas I, II and III are useful for antagonizing endothelin in humans or other mammals .
• Dosage unit compositions may contain such
• compositions may be prepared by procedures
• the compounds of the present invention may be any organic compound having the same properties.
• the compounds of the present invention may be any organic compound having the same properties.
• Topical administeration may also involve the use of
• transdermal administeration such as transdermal patches or
• Injectable preparations for example, sterile injectable
• aqueous or oleagenous suspensions may be formulated according
• the sterile injectable preparation may include
• any bland fixed oil may be employed including synthetic mono-
• fatty acids such as oleic acid
• excipient such as cocoa butter and polyethylene glycols which
• Solid dosage forms for oral administeration may include
• the active compound may be admixed with at
• inert diluent such as sucrose lactose or starch.
• Such dosage forms may also comprise, as is normal practice,
• Tablets and pills can additionally
• Liquid dosage forms for oral administeration may include
• compositions may also comprise
• adjuvants such as wetting agents, emulsifying and suspending
• compositions of the present invention can also be sweetening, flavoring, and perfuming agents.
• sweetening, flavoring, and perfuming agents can also be sweetening, flavoring, and perfuming agents.
• the compounds of the present invention can also be sweetening, flavoring, and perfuming agents.
• sweetening, flavoring, and perfuming agents can also be sweetening, flavoring, and perfuming agents.
• liposomes are generally derived from phospholipids or
• Liposomes are formed by mono- or
• compositions in liposome form can contain,
• preferred lipids are the phospholipids and phosphatidyl
• cholines lecithins
• a representative solid dosage form for example, a tablet
• anticancer drugs or methods including, but not limited to,
• hormonal agents such as leuprolide (Lupron ) ; gonadorelin
• bicalutamide nilutamide; flutamide; vitamin D; vitamin D
• estrogen and estrogen analogues such as
• inhibitors such as finasteride; bone-seeking radionuclides,
• brachytherapy which is the
• trastuzumab Herceptin
• anti-Herceptin trastuzumab
• angiogenic agents such as thrombospondin peptide or kringle 5;
• agents such as docitaxil and paclitaxil; estramustine; gemcytabine; adriamycin; doxorubicin; daunorubicin;
• cytokines such as IL-2
• PPAR agonists such as thiazolidine
• therapeutics including sense and anti-sense genes
• cholesterol lowering drugs such as lovastatin, pravastatin,
• radionucleotides include radionucleotides; antibody-coupled cytotoxic agents; antibody-
• the therapeutically active agents When administered as a combination, the therapeutically active agents.
• the therapeutically active agents When administered as a combination, the therapeutically active agents.
• compositions which are
• agents can be given as a single composition.
• the compounds invention can be used in combination with one or more co-therapeutic agents which
• estrogen receptor modulators such as raloxifene
• the compounds of the invention can additionally be any organic compound having the same side chain aromaticity.
• the compounds of the invention can additionally be any organic compound having the same side chain aromaticity.
• osteoarthritis arthritis, osteoarthritis, Paget ' s disease, osteohalisteresis,
• osteomalacia hypercalcemia of malignancy, osteopenia due to
• ABT-627 was formulated in 2.5 and 10 mg doses.
• liquid formulation of ABT-627 was also prepared as follows: 1
• PSA serum Prostate Specific Antigen
• PSA acid phosphatase
• IL-6 acid phosphatase
• Chromagranin-A values Chromagranin-A
• PSA specific antigen
• the first antibody the first antibody
• the Solid Phase is
• ABT-627 demonstrating the effectivness of ABT-627 as an agent for treating prostate cancer.
• ACP Acid Phosphatase
• alpha-naphthyl phosphate to alpha-naphthoi and inorganic
• nm is directly proportional to ACP activity in the sample.
• Chromagranin-A Levels The effect of ABT-627 adminstration on Chromagranin-A
• LOD Detection
• Chromagranin-A was higher for subjects treated with 2.5 mg/day
• anterior and posterior projections of the total body can be
• bone scans indicated a decrease in
• VAS Visual Analog Scale
• the log also contained a table on which was
• the logs measured the score by measuring the distance (in mm)
• medication dose refers to a dose equal to one single dose a
• the weekly VAS scores were calculated excluding the
• VAS score the day with the highest analgesic use was discarded.
• the weekly mean VAS score was used to define subjects as responders or non-responders .
• a subject was considered a
• pain analgesic consumption was reduced by at least 25% during
• the response defined as the time from baseline to the last
• Bone markers include bone alkaline phosphatase
• BAP deoxypridinoline
• N-telopeptide of Type I collagen
• RIA radioimmunoassay
• telopeptide levels decreased in subjects treated with ABT-627

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Physical Education & Sports Medicine (AREA)
• Diabetes (AREA)
• Endocrinology (AREA)
• Rheumatology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Pain & Pain Management (AREA)
• Neurosurgery (AREA)
• Reproductive Health (AREA)
• Nutrition Science (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Urology & Nephrology (AREA)
• Surgery (AREA)
• Oncology (AREA)
• Gastroenterology & Hepatology (AREA)
• Immunology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Plural Heterocyclic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (17)

Applications Claiming Priority (2)

Publications (2)

Family

ID=24539436

Family Applications (1)

Country Status (22)

Cited By (8)

Families Citing this family (1)

Citations (1)

Family Cites Families (4)

• 2001
  • 2001-07-24 TW TW090118053A patent/TWI306760B/zh active
  • 2001-08-06 CA CA002416879A patent/CA2416879C/en not_active Expired - Fee Related
  • 2001-08-06 WO PCT/US2001/024716 patent/WO2002011713A2/en not_active Ceased
  • 2001-08-06 IL IL15376901A patent/IL153769A0/xx unknown
  • 2001-08-06 SK SK178-2003A patent/SK1782003A3/sk unknown
  • 2001-08-06 AT AT01959595T patent/ATE465728T1/de not_active IP Right Cessation
  • 2001-08-06 CN CNA018169929A patent/CN1635878A/zh active Pending
  • 2001-08-06 AR ARP010103755A patent/AR031122A1/es not_active Application Discontinuation
  • 2001-08-06 AU AU2001281134A patent/AU2001281134B2/en not_active Ceased
  • 2001-08-06 AU AU8113401A patent/AU8113401A/xx active Pending
  • 2001-08-06 DE DE60141979T patent/DE60141979D1/de not_active Expired - Lifetime
  • 2001-08-06 EP EP01959595A patent/EP1347751B1/en not_active Expired - Lifetime
  • 2001-08-06 PE PE2001000782A patent/PE20020273A1/es not_active Application Discontinuation
  • 2001-08-06 PL PL01366160A patent/PL366160A1/xx unknown
  • 2001-08-06 HU HU0302977A patent/HUP0302977A2/hu unknown
  • 2001-08-06 JP JP2002517050A patent/JP4217068B2/ja not_active Expired - Fee Related
  • 2001-08-06 BR BR0108865-3A patent/BR0108865A/pt not_active Application Discontinuation
  • 2001-08-06 NZ NZ523562A patent/NZ523562A/en unknown
  • 2001-08-06 KR KR10-2003-7001735A patent/KR20030027007A/ko not_active Ceased
  • 2001-08-06 MX MXPA03000984A patent/MXPA03000984A/es active IP Right Grant
• 2003
  • 2003-01-09 ZA ZA200300253A patent/ZA200300253B/en unknown
  • 2003-02-06 NO NO20030593A patent/NO20030593D0/no not_active Application Discontinuation
  • 2003-02-21 BG BG107577A patent/BG107577A/bg unknown
• 2006
  • 2006-11-08 JP JP2006302713A patent/JP2007084564A/ja active Pending
  • 2006-11-08 JP JP2006302712A patent/JP2007063288A/ja active Pending

Patent Citations (1)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events